Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevirapine toxicogenomics case-control study of hepatotoxicity and severe cutaneous toxicity
2005-004321-26Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nevirapine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Association between nevirapine-related adverse events and genetic polymorphisms. Started Dec 2005; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-004321-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004321-26.